Technology ID

Prefusion HPIV F Immunogens and Their Use.

Lead Inventor
Kwong, Peter (NIAID)
Chuang, Gwo-Yu (NIAID)
Xu, Kai (NIAID)
Zhou, Tongqing (NIAID)
Tsybovsky, Yaroslav (Leidos Biomedical Research, Inc)
Druz, Aliaksandr (NIAID)
Lanzavecchia, Antonio (Institute for Research in Biomedicine (IRB))
Corti, Davide (Institute for Research in Biomedicine (IRB))
Stewart-Jones, Guillaume (NIAID)
Zhang, Baoshan (NIAID)
Yang, Yongping (NIAID)
Thomas, Paul (NIAID)
Ou, Li (NIAID)
Kong, Wing-pui (NIAID)
Mascola, John (NIAID)
Lead IC
Human parainfluenza virus (hPIV) is an RNA-based paramyxovirus that causes respiratory infections in children and adults. There are four serotypes that can result in a myriad of diseases of the respiratory tract including croup, bronchitis, and pneumonia (Mao et al., 2012). hPIV is a leading cause of respiratory tract infection and hospitalization among children under 5, only surpassed by the respiratory syncytial virus (RSV). Currently, there are limited treatment options and no approved vaccines. Recently, studies showed that a large proportion of neutralizing antibodies preferentially recognize exposed epitopes in the prefusion conformation of the RSV F protein, which together with other evidence suggests that creation of stabilized prefusion F protein immunogens might be a universal strategy to develop vaccine candidates for inducing protective immune responses in RSV and other related viruses, such as hPIV.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases created immunogenic PIV fusion (F) glycoproteins for types 1,2,3 and 4 (hPIV1, hPIV2, hPIV3 and hPIV4) that have been modified to stabilize the prefusion conformation.

These stabilized prefusion F immunogens, especially hPIV3, induced high titer neutralizing responses in mice and rhesus macaques, and should thus serve as promising candidates for the prevention of PIV infection in humans.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.
Commercial Applications
  • hPIV vaccines for people of all ages;
  • Specific focus on the elderly and young children
Competitive Advantages
  • Use as a multivalent hPIV vaccine;
  • Use in combination with influenza or RSV vaccine compositions;
  • hPIV3 neutralizing titers induced in both mice and rhesus macaques were substantially higher than the highest PIV3 neutralizing titers observed in a cohort of over 100 humans.
Licensing Contact: